Centivo has appointed Lisa Bielamowicz as chief health officer, bringing onto its executive team a physician who has spent most of her career advising American health systems rather than running a health plan.
Bielamowicz moves into the role from the company's own board, where she had been serving as a strategic adviser. She is the co-founder of Gist Healthcare, a strategic advisory firm working with provider systems, and before that was chief medical officer of the Advisory Board, the research and consulting business whose work shaped how a generation of American hospital executives read their own markets.
The appointment was announced alongside a second executive hire, with James Parr joining as chief commercial officer after more than twenty years at Cigna, a spell as senior vice president and head of sales at Collective Health, and earlier work as a producer at Lockton.
Ashok Subramanian, co-founder and chief executive of the company, framed both hires around market expansion, saying the new leaders put it in a strong position as it launches in new markets.
The shape of the hire is worth reading. Centivo sells a primary care centred health plan to self funded employers, which puts it in direct competition with the established national carriers for a slice of the employer market that is actively looking for an alternative. A company in that position has two distinct problems. The first is clinical credibility with the provider systems whose doctors it needs inside its networks. The second is distribution through the benefits consultants and brokers who decide which plans an employer ever sees.
Taken together the two appointments address one each. Bringing in an adviser who has spent years inside provider strategy answers the first, and recruiting a career carrier and benefits distribution executive answers the second. Hiring for both in a single announcement suggests a company moving from proving a product to selling it at scale, which is the transition at which narrow network plans have historically either found their market or stalled.
Promoting a strategic adviser off the board into an executive seat is also a particular kind of decision. It shortens the learning curve, because the incoming officer already knows the business, its numbers and its board. It narrows the field of view at the same time, since an adviser who helped shape the strategy is unlikely to be the person who overturns it. For a company at this stage that trade is usually worth making, and it is a trade rather than a pure gain.
The company is privately held and does not disclose membership or revenue, so the external evidence for how well the model is working remains thin. What the market can observe is hiring, and a business that adds a chief health officer and a chief commercial officer in the same week is not hiring to hold position.
